Capstone Therapeutics says prior quarterly EPS figures should no longer be relied upon after share-count error
CAPS•Restated share counts and internal control weakness
The company said its audit committee concurred on Aug. 10, 2026, and amendments on Form 10-Q/A were filed for June 30, 2025, Sept. 30, 2025, and March 31, 2026.
Capstone restated March 31, 2025 weighted-average shares to 1,555,566 from 5,190,251, revising net loss per share to $(1.56) from $(0.47). Management said it identified a material weakness in internal controls tied to EPS share-count computation, while net loss and balance sheet amounts were not affected.
Capstone Therapeutics flags non-reliance on quarterly financial statements
Capstone Therapeutics said prior quarterly financial statements should no longer be relied upon because of errors in weighted-average share counts.
The issue affects basic and diluted net loss per share for the quarters ended June 30, 2025, Sept. 30, 2025, and the comparative quarter ended March 31, 2025.
